µ±Ç°Î»Ö㺠Ê×Ò³ > ҽѧ >¼ÒÈËθ°©IVÆÚ×ªÒÆ¸¹Ç»£¬¸Ð¾õÿһÌì¶¼±»Éú»î´·µÄ̧²»ÆðÍ·

¼ÒÈËθ°©IVÆÚ×ªÒÆ¸¹Ç»£¬¸Ð¾õÿһÌì¶¼±»Éú»î´·µÄ̧²»ÆðÍ·

×÷Õß qiuyt03
À´Ô´: Сľ³æ 900 18 ¾Ù±¨Ìû×Ó
+¹Ø×¢

Ò»ÆÚÖÎÁƽøÐÐÖУ¬Ï£Íû´ó¼ÒÄÜÌṩµãÏ£Íû£¬»òÕß¼õÉÙ²¡Í´µÄ·½·¨

 ·µ»ØÐ¡Ä¾³æ²é¿´¸ü¶à

½ñÈÕÈÈÌû
  • ¾«»ªÆÀÂÛ
  • bjgame3282

    ºÈ¶ìѪ£¬ÓÐÆæ¼£·¢Éú¡£Äã¿ÉÒԲ鿴Öйú¹ÅÊéÓмÇÔØ¡£ÎÒ¼ÒÇ×ÆÝ¾Í·¢ÉúÁËÆæ¼££¬ÖÐÍíÆÚ³¦°©¸Î×ªÒÆ£¬¶ìѪ°ïÖúÁÙ´²ÖÎÓú¡£ÏÖÔÚ15ÄêÁË¡£¡£¡£

  • bjgame3282

    ÓÐÌõ¼þ¾Í¶àºÈһЩ¡£Ã»Ìõ¼þ¾ÍÉÙºÈһЩ¡£ºÈÒ»¶Îʱ¼ä²î²»¶àÁ½¸öÔ°ɡ£È¥¸´²éCEA Ææ¼£°ãϽµ

  • bjgame3282

    Èç¹ûÊÇÖ±½ÓºÈ¶ìѪ ½¨ÒéÿÖܺÈ1-2´Î¡£Èç¹û×ö³É¶³¸É·Û ÿÌì³ÔÒ»´Î Ò»´ÎÎå¿Ë¡£ÔçÉÏÆðÀ´¿Õ¸¹¡£

  • haibian111

    ÎÒÃÇÖÐÒ½Ò©£¬ÒûʳÕý³£µÄÇé¿öÏ£¬Ò»°ã¸¹²¿×ªÒƶ¼ÄÜÓÐЧ¡£

  • y-l-wang

    θ°©ivÆÚÓÐ×ªÒÆ¹À¼ÆÒ½ÉúÒѾ­ºÍ¼ÒÊô˵µÃºÜÃ÷°×ÁË£¬¼ÓÇ¿²¡ÈËÓªÑø£¬Î人µÄʯººÆ½½ÌÊÚÊÇÖ×ÁöÁÙ´²ÓªÑøÖ§³ÖµÄµÚÒ»ÈË£¬Èç¹ûÓÐÌõ¼þÈ¥ÕÒÒ»ÌË£»ÁíÍâÕùÈ¡²Î¼ÓÐÂÒ©µÄÁÙ´²ÊÔÑ飬zolbetuximab
    pamiparib
    bemarituzumab
    fruquintinib
    bemarituzumab
    ipilimumab
    folinate; gimeracil; oteracil potassium; tegafur
    ipilimumab
    fruquintinib
    sintilimab
    ipilimumab
    andecaliximab
    avelumab
    pamiparib
    -
    avelumab
    rivoceranib
    encequidar; paclitaxel
    andecaliximab
    masitinib mesylate
    -
    tislelizumab
    -
    -
    tislelizumab
    encequidar; paclitaxel
    nimotuzumab
    ipilimumab
    nimotuzumab
    bemarituzumab
    sintilimab
    -
    -
    sintilimab
    camrelizumab
    paclitaxel
    rivoceranib
    trastuzumab
    avelumab
    È«Çòθ°©·½Ãæ´ó¸ÅÊÇÕ⼸¸öÒ©Îï½øÈëÁËÁÙ´²ÈýÆÚ£¬Äã²é²éÄÄЩ¸öÊʺÏÄãÇ×ÊôµÄ¡£
    ËäÈ»À§ÄÑÖØÖØ£¬µ«ÊÇ»¹ÊÇÆÚÍûÆæ¼£¬

²ÂÄãϲ»¶
ÏÂÔØÐ¡Ä¾³æAPP
Óë700Íò¿ÆÑдïÈËËæÊ±½»Á÷
  • ¶þάÂë
  • IOS
  • °²×¿